



## OpGen Announces Closing of Public Offering of Common Stock

March 29, 2019

GAITHERSBURG, Md., March 29, 2019 (GLOBE NEWSWIRE) -- [OpGen, Inc.](#) (Nasdaq: OPGN) announced today the closing of its previously announced underwritten public offering of 9 million shares of its common stock at a public offering price of \$0.60 per share. All of the shares were sold by OpGen. The aggregate gross proceeds to OpGen from the offering, before deducting the underwriting discount and commissions and offering expenses, were approximately \$5.4 million.

Aegis Capital Corp. acted as the sole book-running manager for the offering.

The shares were issued pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC). A final prospectus was filed with the SEC on March 26, 2019. A copy of the final prospectus relating to the offering, when available, may be obtained by contacting Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019, (212) 813-1010 or by accessing the SEC's website, [www.sec.gov](http://www.sec.gov).

### About OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

Our molecular diagnostics and informatics products, product candidates and services combine our Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with our proprietary, curated MDRO knowledgebase. We are working to deliver our products and services, some in development, to a global network of customers and partners. The Acuitas AMR Gene Panel (RUO) is intended for Research Use Only and is not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures. For more information, please visit [www.opgen.com](http://www.opgen.com).

OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.

### OpGen Contact:

Michael Farmer  
Vice President, Marketing  
(240) 813-1284  
[mfarmer@opgen.com](mailto:mfarmer@opgen.com)  
[InvestorRelations@opgen.com](mailto:InvestorRelations@opgen.com)

### Press Contact:

Matthew Bretzius  
[FischTank Marketing and PR](#)  
[matt@fischtankpr.com](mailto:matt@fischtankpr.com)

### Investor Contacts:

Joe Green  
Edison Group  
[jgreen@edisongroup.com](mailto:jgreen@edisongroup.com)



Source: OpGen, Inc.